BioStem 10-Q: Going Concern, $1.0M Cash, Unpaid $10M BioTissue Bill, DOJ Probe
BSEM sits 37% above its 52-week low of $1 on elevated volume (2.1× avg).
Summary
BioStem's Q3 10-Q shows $971,145 of cash, a going-concern warning, an overdue $10M BioTissue payment now immediately due, and a new DOJ False Claims Act inquiry — against a $11.4M quarterly loss on $7.6M of revenue.
Key Events · Earnings and Guidance · BSEM
-
Going Concern With $971,145 of Cash
Cash and equivalents fell to $971,145 at September 30, 2026 from $29,549,018 at December 31, 2025, against $22,169,888 of current liabilities. Management states substantial doubt exists about the ability to continue as a going concern for at least one year.
-
$10M BioTissue Payment Overdue
The $10,000,000 Clearance Payment was due September 15, 2026 and has not been made; it is recorded as a current consideration payable and is immediately due and payable under Amendment No. 1. A further $1,000,000 in extension payments was expensed in Q3.
-
DOJ False Claims Act Inquiry
In September 2026 the Company received a Civil Investigative Demand from the U.S. Department of Justice under the False Claims Act and Anti-Kickback Statute seeking documents on pricing and ASP reporting for its skin substitute products and distributor arrangements.
-
Q3 Loss Widens, Margin Collapses
Q3 revenue was $7,640,885 versus $10,473,402 a year earlier, with a net loss of $11,375,654 ($0.64 per share) versus net income of $761,052. Gross margin fell to 56% from 88% as cost of goods sold rose 178% to $3,346,797.
Analysis · BSEM · Life Sciences
The headline numbers were already out via the same-day 8-K, but the full 10-Q is where the survival math becomes explicit. Cash fell to $971,145 against $22.2M of current liabilities, and management states substantial doubt about the ability to continue as a going concern. The $10.0M BioTissue Clearance Payment was due September 15, 2026 and remains unpaid, so it is now immediately due and payable and sits on the balance sheet as a current liability. Layered on top is a September 2026 DOJ Civil Investigative Demand under the False Claims Act and Anti-Kickback Statute covering pricing and ASP reporting for the skin substitute products. The one lever left is the $40M Roth committed equity facility, but sales cannot begin until April 9, 2027 absent a waiver, and the September placement blocks variable-rate transactions for six months after its effective date. Revenue quality also deteriorated: gross margin fell to 56% from 88% as physician-office sales dropped 92% under the new CMS $127.14 per square centimeter rate, with hospital sales from the BioTissue assets ($6.83M) now carrying the top line.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BSEM was trading at $1.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.3M. The 52-week trading range was $1.00 to $8.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.